Ray Barlow, chief executive of e-Therapeutics plc (LON:ETX) caught up with Proactive to update on developments at the drug developer.
Last month they unveiled the results of its strategic review under the new chief executive.
Following the review, the company decided to invest in its network-driven drug discovery (NDD) platform in creating new drugs, while continuing to control costs.
''The first three months of my tenure have been internally-facing .. we're now very purposefully going out to the world'', Barlow says.
''We're going to undertake a very systematic business development exercise, we're going to engage with biopharmaceutical companies ... we're also going to engage with companies that may not be traditionally associated with this space - such as the googles of this world''.